Related Experiment Video
Updated: May 2, 2026
07:51
Development and Functionalization of Electrolyte-Gated Graphene Field-Effect Transistor for Biomarker Detection
Published on: February 1, 2022
2.9K
Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor
Seon Joo Park1, Hyun Seok Song2, Oh Seok Kwon3
11] World Class University program of Chemical Convergence for Energy & Environment, School of Chemical and Biological Engineering, Seoul National University, 151-742, Korea [2].
Scientific Reports
|March 12, 2014
Summary
This study introduces a novel dopamine (DA) biosensor using bio-nanotechnology for rapid, sensitive detection. The new device achieves a 10 pM minimum detectable level, significantly improving upon existing technologies for disease diagnosis.
Area of Science:
- Bio-nanotechnology
- Molecular detection
- Biosensor development
Background:
- Dopamine (DA) detection is crucial for diagnosing neurological diseases like Parkinson's and Alzheimer's.
- Developing rapid, sensitive, and selective molecular detection methods remains a significant challenge.
- Existing biosensors often lack the required performance for early disease diagnosis.
Purpose of the Study:
- To develop a high-performance dopamine biosensor using novel bio-nanotechnology.
- To improve sensitivity, selectivity, and response time for dopamine detection.
- To create a reliable tool for early diagnosis of dopamine-associated diseases.
Main Methods:
- Fabrication of dopamine receptor-containing nanovesicles (DRNCNs) using carboxylated poly(3,4-ethylenedioxythiophene) (CPEDOT) nanomaterial transistors.
- Construction of nanovesicles expressing human dopamine receptor D1 (hDRD1) from HEK-293 cells.
- Integration of DRNCNs into a liquid-ion gated field-effect transistor (FET) system for dopamine detection.
Main Results:
- The developed biosensor demonstrated high sensitivity and excellent selectivity for dopamine detection in liquid state.
- Achieved an unprecedented minimum detectable level (MDL) of 10 pM for dopamine, 10 times more sensitive than previous CP-based sensors.
- Exhibited a rapid response time of less than 1 second and maintained selectivity in human serum.
Conclusions:
- The novel bio-nanotechnology approach successfully created a high-performance dopamine biosensor (DRNCNs).
- The FET-type DRNCN biosensor offers significant improvements in sensitivity, selectivity, and speed for dopamine detection.
- This technology holds promise for early and accurate diagnosis of neurological disorders associated with dopamine levels.
